跳转至内容
Merck

S0758

Sigma-Aldrich

磺胺苯吡唑

≥98%

别名:

4-氨基-N-(1-苯基-1H-吡唑-5-基)苯磺酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H14N4O2S
CAS号:
分子量:
314.36
EC 号:
MDL编号:
UNSPSC代码:
12352204
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98%

表单

powder

溶解性

ethanol: 25 mg/mL, clear, colorless to yellow

储存温度

2-8°C

SMILES字符串

Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3

InChI

1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

InChI key

QWCJHSGMANYXCW-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

磺胺苯吡唑已用作定量分析红景天提取物对细胞色素P450 2C9(cyp2c9)抑制作用的阳性对照。也用作内皮细胞和微粒体制品中的细胞色素P450 2C9 (cyp2c9)抑制剂。

生化/生理作用

抗细菌。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸(氧化应激和AP-1活化增加)的促炎症和致动脉粥样硬化作用。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸(氧化应激和AP-1活化增加)的促炎症和致动脉粥样硬化作用。抑制缓激肽诱导的tPA释放。

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Noncompetitive inhibition of human CYP 2C9 in vitro by a commercial Rhodiola rosea product
Thu OKF, et al.
Pharmacology Research & Perspectives, 5(4), e00324-e00324 (2017)
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform
Moraes CB, et al.
SLAS discovery, 24(3), 346-361 (2019)
Simon Lucas et al.
Journal of medicinal chemistry, 51(19), 6138-6149 (2008-09-04)
Pharmacophore modeling of a series of aldosterone synthase (CYP11B2) inhibitors triggered the design of compounds 11 and 12 by extending a previously established naphthalene molecular scaffold (e.g., present in molecules 1 and 2) via introduction of a phenyl or benzyl
Vienna E Brunt et al.
The Journal of physiology, 590(15), 3523-3534 (2012-06-08)
While it is accepted that NO is responsible for ∼60% of the plateau in cutaneous thermal hyperaemia, a large portion of the response remains unknown. We sought to determine whether the remaining ∼40% could be attributed to EDHF-mediated activation of
Zhiping Jin et al.
Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)
Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门